Manfred Welslau, MD: Biosimilars and Patient Access

Manfred Welslau, MD, Onkologie Aschaffenburg, Germany, discusses the benefits that biosimilars have in terms of patient access.
July 31, 2019



Transcript:

Perhaps, for the developing countries, biosimilars are a way to get more people on therapy. I’m thinking of China, thinking of India, thinking of Mexico and the Middle East countries. In these health systems, I think a lot of people are pending getting these medications, so this is a way to help people in these countries to be on therapy.
 

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.